Glaukos this week announced several executive leadership changes that will take place on April 1.
Joseph Gilliam is appointed as president and COO. He previously served as the CFO and SVP of corporate development for the San Clemente, California-based ophthalmic medtech and pharma company since 2017.
Here are Glaukos’ new executive committee appointments:
- Chris Calcaterra will assume the new role of EVP of global commercial operations. He joined Glaukos in 2008 as chief commercial officer, and served as COO since February 2017.
- Alex Thurman will succeed Gilliam to become SVP and CFO. He joined Glaukos as VP of global tax administration in July 2016 and has served as VP of finance since December 2016.
- Tomas Navratil will become the company’s new chief development officer. He has served as SVP of research and development since joining the company in late 2020.
“I am confident these outstanding and proven leaders will continue to successfully drive Glaukos forward in the next phase of our pioneering journey and help further advance our mission to transform the treatment of chronic eye diseases for the benefit of patients worldwide,” chairperson and CEO Thomas Burns said in a news release.
“At the same time, I want to extend my sincere congratulations to my friend and colleague Chris Calcaterra on his requested transition into his new role. Chris has been instrumental in the growth and development of Glaukos since joining our management team nearly fourteen years ago. I am confident he will continue to play an integral role in our success in his new position that will provide Chris with the opportunity to step back from his day-to-day administrative responsibilities and spend more time with his family while continuing to focus on our global commercialization operations, his deep customer relationships built over the past 35 years and ongoing strategic counsel to our executive and commercial leadership teams.”
